Immune dysfunctions: New targets of drug discovery for alzheimerapos;s disease and other cognitive disorders

Harbans Lal, Michael J. Forster, Konrad C. Retz, Barry Reisberg

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

The development of treatments applicable to Alzheimerapos;s disease and other age‐associated dementias represents a serious challenge to biomedical research. It is suggested that advances in the understanding of basic etiologic mechanisms in these disorders would provide the most direct avenues to discovery of preventive and arrestive treatments. An overview of research relating to the potential involvement of immune dysfunctions in the etiology of Alzheimerapos;s and other central nervous system (CNS) diseases is reviewed as this was presented and discussed in a recent satellite symposium, “Autoimmunity: Its Role in Alzheimerapos;s Disease and Other Behavioral Dysfunctions,” held at the 17th Annual Meeting of The Society for Neuroscience. It is predicted that some future research may focus on immunological dysfunctions as targets for the discovery and development of drugs for treatment of Alzheimerapos;s dieseas and other cognitive disorders.

Original languageEnglish
Pages (from-to)95-99
Number of pages5
JournalDrug Development Research
Volume15
Issue number2-3
DOIs
StatePublished - 1988

Keywords

  • aging
  • autoimmunity
  • dementias
  • drug development
  • dyslexia
  • immune system
  • systemic lupus erythematosus

Fingerprint Dive into the research topics of 'Immune dysfunctions: New targets of drug discovery for alzheimerapos;s disease and other cognitive disorders'. Together they form a unique fingerprint.

  • Cite this